Resistance to human immunodeficiency virus type 1 (HIV-1) generated by lentivirus vector-mediated delivery of the CCR5{Delta}32 gene despite detectable expression of the HIV-1 co-receptors.
It has previously been demonstrated that there are two distinct mechanisms for genetic resistance to human immunodeficiency virus type 1 (HIV-1) conferred by the CCR5Delta32 gene: the loss of wild-type CCR5 surface expression and the generation of CCR5Delta32 protein, which interacts with CXCR4. To analyse the protective effects of long-term expression of the CCR5Delta32 protein, recombinant lentiviral vectors were used to deliver the CCR5Delta32 gene into human cell lines and primary peripheral blood mononuclear cells that had been immortalized by human T-cell leukemia virus type 1. Blasticidin S-resistant cell lines expressing the lentivirus-encoded CCR5Delta32 showed a significant reduction in HIV-1 Env-mediated fusion assays. It was shown that CD4(+) T lymphocytes expressing the lentivirus-encoded CCR5Delta32 gene were highly resistant to infection by a primary but not by a laboratory-adapted X4 strain, suggesting different infectivity requirements. In contrast to previous studies that analysed the CCR5Delta32 protective effects in a transient expression system, this study showed that long-term expression of CCR5Delta32 conferred resistance to HIV-1 despite cell-surface expression of the HIV co-receptors. The results suggest an additional unknown mechanism for generating the CCR5Delta32 resistance phenotype and support the hypothesis that the CCR5Delta32 protein acts as an HIV-suppressive factor by altering the stoichiometry of the molecules involved in HIV-1 entry. The lentiviral-CCR5Delta32 vectors offer a method of generating HIV-resistant cells by delivery of the CCR5Delta32 gene that may be useful for stem cell- or T-cell-based gene therapy for HIV-1 infection.
Jin
Qingwen
Q
Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Marsh
Jon
J
Indiana University Vector Production Facility, Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Cornetta
Kenneth
K
Indiana University Vector Production Facility, Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.|Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Alkhatib
Ghalib
G
Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
D015496:CD4-Positive T-Lymphocytes / Q000821:virology; D002460:Cell Line; D002461:Cell Line, Transformed; D002472:Cell Transformation, Viral; D015686:Gene Products, env / Q000235:genetics / Q000378:metabolism; D005822:Genetic Vectors; D015497:HIV-1 / Q000378:metabolism* / Q000472:pathogenicity*; D006367:HeLa Cells; D015368:Human T-lymphotropic virus 1 / Q000502:physiology; D006801:Humans; D016086:Lentivirus / Q000235:genetics*; D007963:Leukocytes, Mononuclear; D019713:Receptors, CCR5 / Q000235:genetics* / Q000378:metabolism*; D014161:Transduction, Genetic
D015686:Gene Products, env; D019713:Receptors, CCR5
Science. 1996 Jun 28;272(5270):1955-8
8658171
Mol Biotechnol. 1999 Dec 15;13(3):223-45
10934535
Cell. 1996 Jun 28;85(7):1149-58
8674120
J Exp Med. 2007 Apr 16;204(4):705-14
17389241
Science. 1996 Sep 27;273(5283):1856-62
8791590
Mol Med. 1997 Jan;3(1):23-36
9132277
Immunol Rev. 2000 Oct;177:99-111
11138790
J Biol Chem. 2002 Jan 18;277(3):2287-301
11604406
Virology. 2007 Aug 1;364(2):281-90
17428518
AIDS. 1997 Sep;11(11):F73-8
9302436
J Virol. 1994 Sep;68(9):5411-22
8057423
Exp Mol Pathol. 2000 Jun;68(3):133-8
10816381
Nature. 1996 Jun 20;381(6584):661-6
8649511
Nature. 1981 Dec 24;294(5843):770-1
6275274
J Biol Chem. 2001 Dec 14;276(50):46975-82
11600494
Int J Cancer. 1983 Apr 15;31(4):413-20
6601065
Eur J Immunol. 2008 Feb;38(2):537-49
18200497
J Virol. 2004 Mar;78(5):2277-87
14963124
J Virol. 1994 Apr;68(4):2570-7
8139036
Nature. 1997 Jul 17;388(6639):238
9230431
J Virol. 2007 Aug;81(15):8041-9
17522201
J Virol. 1998 Nov;72(11):8463-71
9765382
J Biol Chem. 1997 Dec 5;272(49):30603-6
9388191
J Virol. 1996 Oct;70(10):7241-6
8794375
Lancet. 1997 Apr 26;349(9060):1219-20
9130946
Cell. 1996 Jun 28;85(7):1135-48
8674119
Gene Ther. 2005 Mar;12(6):467-76
15703764
Methods Mol Biol. 2006;332:141-57
16878690
Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):5215-20
10220446
Science. 1996 May 10;272(5263):872-7
8629022
J Immunol. 1996 Dec 1;157(11):5076-84
8943417
Hum Gene Ther. 2001 Jun 10;12(9):1103-8
11399231
EMBO J. 2004 Jan 14;23(1):66-76
14685276
J Virol. 2005 Sep;79(18):11677-84
16140745
Eur J Med Res. 2007 Oct 15;12(9):375-84
17933717
Methods Enzymol. 2006;419:439-73
17141066
J Med Primatol. 2006 Aug;35(4-5):236-47
16872287
Science. 1982 Aug 20;217(4561):737-9
6980467
Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):9004-8
7568061
Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1925-30
9050881
J Biol Chem. 2007 Oct 12;282(41):30062-9
17715128
Nature. 1996 Jun 20;381(6584):667-73
8649512
Proc Natl Acad Sci U S A. 1983 Sep;80(17):5402-6
6604273
J Virol. 2000 Aug;74(15):7005-15
10888639